NCT03496506

A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects

A Single-center, Open-label, Two-treatment, One-sequence, Cross-over Study to Investigate the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite, ACT-333679, in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Actelion · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effect of clopidogrel on the pharmacokinetics of selexipag and its active metabolite (ACT-333679) in healthy male adults (by determining the blood concentrations of selexipag and its metabolite). Also, the safety of selexipag when administered alone or with clopidogrel will be assessed.

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	Selexipag	Each film-coated tablet contains 200 microgram (mcg) of selexipag (oral use)
DRUG	Clopidogrel	Each film-coated tablet containing 75 mg of clopidogrel (oral use)

Timeline

• Start date: 2018-03-05
• Primary completion: 2018-05-10
• Completion: 2018-05-18
• First posted: 2018-04-12
• Last updated: 2025-06-22

Locations

1 site across 1 country: Belgium